Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective
- PMID: 27306389
- PMCID: PMC6461391
- DOI: 10.1097/RTI.0000000000000219
Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective
Abstract
Treatment advances have improved outcomes in patients with lung cancer, with a number of targeted therapies and immunotherapies now approved for patients with metastatic disease. Along with longer survival, modern treatment paradigms have increased therapeutic decision-making complexity underscoring informative imaging as paramount in guiding clinical care. In this review, we summarize challenges the thoracic oncologist encounters in common clinical settings. In addition, we explore unmet needs for future investigations with particular focus on positron emission tomography technology and immunotherapies.
Conflict of interest statement
The authors declare no conflicts of interest.
References
-
- Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29. - PubMed
-
- Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005;47:69–80. - PubMed
-
- Cohen MH, Justice R, Pazdur R. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist 2009;14:930–935. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical